Development of a Companion Diagnostic PD-L1 Immunohistochemistry Assay for Pembrolizumab Therapy in Non–Small-cell Lung Cancer

@inproceedings{Roach2016DevelopmentOA,
  title={Development of a Companion Diagnostic PD-L1 Immunohistochemistry Assay for Pembrolizumab Therapy in Non–Small-cell Lung Cancer},
  author={Charlotte Roach and Nancy Ruonan Zhang and Ellie Corigliano and Malinka Jansson and Grant Toland and Gary Ponto and Marisa P. Dolled-Filhart and Kenneth Emancipator and Dave Stanforth and Karina Kulangara},
  booktitle={Applied immunohistochemistry & molecular morphology : AIMM},
  year={2016}
}
A companion diagnostic assay was codeveloped by Dako for pembrolizumab non-small-cell lung cancer clinical trials to detect PD-L1 expression by immunohistochemistry (IHC). This automated IHC assay has been analytically verified and validated using Dako's autostainer Link 48 and 22C3 mouse anti-PD-L1 monoclonal antibody to detect the PD-L1 expression in formalin-fixed paraffin-embedded human tumor tissue specimens. The PD-L1 22C3 IHC assay was optimized for high sensitivity and specificity… CONTINUE READING

Similar Papers

Citations

Publications citing this paper.
SHOWING 1-10 OF 35 CITATIONS

Clinical impact of PD-L1 and PD-1 expression in squamous cell cancer of the vulva

  • Journal of Cancer Research and Clinical Oncology
  • 2019
VIEW 1 EXCERPT
CITES RESULTS

Clinical and molecular characteristics of pulmonary sarcomatoid carcinoma

  • The Korean journal of internal medicine
  • 2018
VIEW 1 EXCERPT
CITES METHODS

References

Publications referenced by this paper.
SHOWING 1-10 OF 17 REFERENCES